Mark Plavsic net worth and biography

Mark Plavsic Biography and Net Worth

Insider of Fate Therapeutics
Dr. Mark Plavsic is Chief Technical Officer at Fate Therapeutics, overseeing the company’s cell therapy manufacturing, supply chain, and technical operations. Dr. Plavsic has more than 20 years of broad experience in process development and end-to-end product development of large scale commercial biologics. Prior to joining Fate Therapeutics, Dr. Plavsic served as Chief Technical Officer at Lysogene, a late stage clinical development gene therapy company with headquarters in Paris, France. Before joining Lysogene, Dr. Plavsic was SVP of CMC at Torque Therapeutics, Inc., and was Head of Product Biosafety at Genzyme/Sanofi, where he was responsible for process improvements and viral safety of all commercial biological products and associated manufacturing processes. Previously, Dr. Plavsic was in charge of gene therapy development at Genzyme, overseeing the upstream, downstream, formulation and analytical developments of viral vectors used in gene therapy applications. Before Genzyme, he held various senior leadership positions with AstraZeneca, Q-One Biotech, and Life Technologies, Inc. Dr. Plavsic’s professional experience ranges from Europe, Australasia and USA, and his technical expertise spans across a wide spectrum of drug development and manufacturing activities, including critical animal origin raw materials, cell culture media, GMP QC testing, GLP non-clinical studies, process and analytical development, GMP manufacturing, contract manufacturing, and supply chain. Dr. Plavsic received his Ph.D. in Virology and Molecular Cell Biology, M.Sc. in Virology and Immunology, and Doctor of Veterinary Medicine (D.V.M.) degree from the University of Belgrade in Yugoslavia. He has a Board certification in Microbiology, subspeciality Virology, from the American College of Veterinary Microbiologists.

What is Mark Plavsic's net worth?

The estimated net worth of Mark Plavsic is at least $2.84 million as of July 5th, 2022. Dr. Plavsic owns 127,123 shares of Fate Therapeutics stock worth more than $2,839,928 as of September 29th. This net worth approximation does not reflect any other investments that Dr. Plavsic may own. Additionally, Dr. Plavsic receives a salary of $634,510.00 as Insider at Fate Therapeutics. Learn More about Mark Plavsic's net worth.

How old is Mark Plavsic?

Dr. Plavsic is currently 61 years old. There are 4 older executives and no younger executives at Fate Therapeutics. Learn More on Mark Plavsic's age.

What is Mark Plavsic's salary?

As the Insider of Fate Therapeutics, Inc., Dr. Plavsic earns $634,510.00 per year. The highest earning executive at Fate Therapeutics is Mr. J. Scott Wolchko, Founder, CEO, Pres & Director, who commands a salary of $976,000.00 per year. Learn More on Mark Plavsic's salary.

How do I contact Mark Plavsic?

The corporate mailing address for Dr. Plavsic and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected] Learn More on Mark Plavsic's contact information.

Has Mark Plavsic been buying or selling shares of Fate Therapeutics?

During the last ninety days, Mark Plavsic has sold $91,524.59 of Fate Therapeutics stock. Most recently, Mark Plavsic sold 3,719 shares of the business's stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $24.61, for a transaction totalling $91,524.59. Following the completion of the sale, the insider now directly owns 127,123 shares of the company's stock, valued at $3,128,497.03. Learn More on Mark Plavsic's trading history.

Who are Fate Therapeutics' active insiders?

Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.

Are insiders buying or selling shares of Fate Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 380,543 shares worth more than $17,142,741.14. The most recent insider tranaction occured on August, 18th when CFO Edward J Dulac III sold 5,135 shares worth more than $153,074.35. Insiders at Fate Therapeutics own 17.3 % of the company. Learn More about insider trades at Fate Therapeutics.

Information on this page was last updated on 8/18/2022.

Mark Plavsic Insider Trading History at Fate Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/5/2022Sell3,719$24.61$91,524.59127,123View SEC Filing Icon  
See Full Table

Mark Plavsic Buying and Selling Activity at Fate Therapeutics

This chart shows Mark Plavsic's buying and selling at Fate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fate Therapeutics Company Overview

Fate Therapeutics logo
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $22.34
Low: $21.73
High: $22.68

50 Day Range

MA: $28.77
Low: $21.04
High: $36.06

2 Week Range

Now: $22.34
Low: $17.10
High: $66.56


1,259,939 shs

Average Volume

1,448,824 shs

Market Capitalization

$2.17 billion

P/E Ratio


Dividend Yield



Gold is about to SOAR – here’s what you need to do
Everything is lining up perfectly for a historic gold bull run. One gold research firm says they’ve found the best way to get in, for less than $10. MORE here…
Click here for full details.